Susquehanna International Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Susquehanna International Group’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-64,000	Closed	-$330K	–	11282
2019 Q2	$330K	Sell	64,000 -8,800	-12%	-$39.6K	﹤0.01%	8119
2019 Q1	$262K	Buy	+72,800	New	+$315K	﹤0.01%	7456
2018 Q4	–	Sell	-65,500	Closed	-$383K	–	10513
2018 Q3	$383K	Sell	65,500 -43,300	-40%	-$216K	﹤0.01%	6997
2018 Q2	$462K	Buy	108,800 +83,800	+335%	+$423K	﹤0.01%	6951
2018 Q1	$110K	Buy	25,000 +1,700	+7%	+$7.58K	﹤0.01%	8663
2017 Q4	$123K	Sell	23,300 -39,600	-63%	-$242K	﹤0.01%	8611
2017 Q3	$386K	Buy	62,900 +45,500	+261%	+$288K	﹤0.01%	6981
2017 Q2	$126K	Buy	+17,400	New	+$107K	﹤0.01%	8581
2016 Q4	–	Sell	-17,300	Closed	-$162K	–	10445
2016 Q3	$162K	Buy	+17,300	New	+$144K	﹤0.01%	7728
2015 Q4	–	Sell	-16,000	Closed	-$135K	–	10268
2015 Q3	$135K	Buy	+16,000	New	+$271K	﹤0.01%	8988

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Susquehanna International Group's PETX Position: Q3 2019 in Review

Susquehanna International Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 18,949 shares — an estimated $98K sold.

Susquehanna International Group first reported a position in PETX in Q4 2016 and held it in 6 quarters. The position peaked at $3.31M in Q1 2017. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Susquehanna International Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Susquehanna International Group sold 18,949 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $98K.
Susquehanna International Group first reported a position in Aratana Therapeutics, Inc. in Q4 2016 and held it in 6 quarters.
Susquehanna International Group's Aratana Therapeutics, Inc. position peaked at $3.31M in Q1 2017.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.